

Ruth Ann Vleugels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1651460/publications.pdf>

Version: 2024-02-01

72
papers

1,512
citations

394421

19
h-index

345221

36
g-index

73
all docs

73
docs citations

73
times ranked

1550
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Associated Dermatomyositis Following Ipilimumab Therapy. <i>JAMA Dermatology</i> , 2015, 151, 195.	4.1	144
2	Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 776-785.	1.2	141
3	Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis. <i>JAMA Dermatology</i> , 2016, 152, 944.	4.1	114
4	Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 1147.	4.1	75
5	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	1.9	69
6	Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. <i>Current Rheumatology Reports</i> , 2017, 19, 74.	4.7	66
7	Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 291-313.	6.7	61
8	Epidemiology and Treatment of Eosinophilic Fasciitis. <i>JAMA Dermatology</i> , 2016, 152, 97.	4.1	60
9	Dermatomyositis: An Update on Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 339-353.	6.7	54
10	Treatment Options for Pityriasis Rubra Pilaris Including Biologic Agents. <i>JAMA Dermatology</i> , 2014, 150, 92.	4.1	51
11	A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. <i>JAMA Dermatology</i> , 2020, 156, 270.	4.1	49
12	Dermatomyositis Induced by Anti-Tumor Necrosis Factor in a Patient With Juvenile Idiopathic Arthritis. <i>JAMA Dermatology</i> , 2013, 149, 1204.	4.1	40
13	Intravenous immunoglobulin for refractory cutaneous dermatomyositis: A retrospective analysis from an academic medical center. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 654-657.	1.2	37
14	Clinical Features and Comorbidities of Patients With Necrobiosis Lipoidica With or Without Diabetes. <i>JAMA Dermatology</i> , 2019, 155, 455.	4.1	36
15	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. <i>JAMA Dermatology</i> , 2020, 156, 384.	4.1	33
16	Management of cutaneous dermatomyositis. <i>Dermatologic Therapy</i> , 2012, 25, 112-134.	1.7	26
17	Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus. <i>JAMA Dermatology</i> , 2017, 153, 937.	4.1	25
18	Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus. <i>JAMA Dermatology</i> , 2020, 156, 1264.	4.1	24

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. <i>JAMA Dermatology</i> , 2020, 156, 521.	4.1	24
20	Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 701-702.	1.2	23
21	Augmented reality in dermatology: Are we ready for AR?. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1216-1222.	1.2	22
22	Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. <i>JAMA Dermatology</i> , 2019, 155, 494.	4.1	21
23	Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy. <i>JAMA Dermatology</i> , 2015, 151, 1354.	4.1	19
24	Sex and leadership in academic dermatology: A nationwide survey. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 782-784.	1.2	19
25	Clinicopathologic lessons in distinguishing cicatricial alopecia: 7 Cases of lichen planopilaris misdiagnosed as discoid lupus. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e135-e138.	1.2	17
26	Paraproteinemia-Associated Scleredema Treated Successfully With Intravenous Immunoglobulin. <i>JAMA Dermatology</i> , 2014, 150, 788.	4.1	17
27	Teledermatology Perception Differences Between Urban Primary Care Physicians and Dermatologists. <i>JAMA Dermatology</i> , 2015, 151, 339.	4.1	16
28	Segmental stiff skin syndrome (SSS): Two additional cases with a positive response to mycophenolate mofetil and physical therapy. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e237-e239.	1.2	16
29	Characteristics and treatment of adult-onset linear morphea: A retrospective cohort study of 61 patients at 3 tertiary care centers. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 577-579.	1.2	16
30	Characteristics and treatment of postirradiation morphea: A retrospective multicenter analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 19-21.	1.2	16
31	Cutaneous Ulcerations in Anti-MDA5 Dermatomyositis. <i>New England Journal of Medicine</i> , 2019, 381, 465-465.	27.0	15
32	Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 423-425.	1.2	15
33	Cutaneous dermatomyositis in the era of biologicals. <i>Seminars in Immunopathology</i> , 2016, 38, 113-121.	6.1	13
34	Pityriasis rubra pilaris: A study evaluating patient quality of life in 2 populations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 638-640.	1.2	12
35	Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 210-212.	1.2	8
36	Strategies for effective medical student education in dermatology during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e33-e34.	1.2	7

#	ARTICLE	IF	CITATIONS
37	Geographic distribution and environmental triggers of systemic sclerosis cases from 2 large academic tertiary centers in Massachusetts. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 925-927.	1.2	7
38	Dermatomyositis: current and future treatments. <i>Expert Review of Dermatology</i> , 2009, 4, 581-594.	0.3	6
39	Mycophenolate Mofetil for Eosinophilic Fasciitis. <i>JAMA Dermatology</i> , 2020, 156, 595.	4.1	6
40	Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2021, 157, 880-882.	4.1	6
41	Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. <i>JAMA Dermatology</i> , 2021, 157, 735.	4.1	6
42	Immunologic underpinnings and treatment of morphea. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 461-483.	3.0	6
43	Unilateral Gottron Papules in a Patient Following a Stroke. <i>JAMA Dermatology</i> , 2016, 152, 1062.	4.1	4
44	Sharps injuries among US dermatology trainees: A cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 756-758.	1.2	4
45	Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. <i>JAMA Dermatology</i> , 2019, 155, 491.	4.1	4
46	Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review. <i>Archives of Dermatological Research</i> , 2022, 314, 487-489.	1.9	4
47	Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 907-909.	1.2	4
48	Evaluating patient experience and satisfaction with teledermatology for isotretinoin management: a structured qualitative interview study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2698-2701.	2.2	4
49	Genetic diagnosis of immune dysregulation can lead to targeted therapy for interstitial lung disease: A case series and single center approach. <i>Pediatric Pulmonology</i> , 2022, 57, 1577-1587.	2.0	4
50	Pediatric Autoimmune Connective Tissue Diseases: An Update on Disease Characteristics, Associations, and Management. <i>Current Dermatology Reports</i> , 2013, 2, 216-229.	2.1	3
51	Multiple Tense Bullae Localized to the Right Breast in a Woman in Her Seventies. <i>JAMA Dermatology</i> , 2013, 149, 1427.	4.1	3
52	Facing Uncertainty. <i>New England Journal of Medicine</i> , 2019, 381, 2253-2259.	27.0	3
53	Capecitabine-Related Eruption Mimicking Dermatomyositis in 2 Patients With Metastatic Breast Cancer. <i>JAMA Dermatology</i> , 2020, 156, 103.	4.1	3
54	Practice gaps in the evaluation of systemic involvement in patients with cutaneous sarcoidosis presenting to a dermatologist: A retrospective review of 48 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 794-796.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Increased risk of systemic and cardiac sarcoidosis in Black patients with cutaneous sarcoidosis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1178-1180.	1.2	3
56	Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients. <i>JAAD International</i> , 2021, 3, 111-114.	2.2	3
57	Recognition and Management of Cutaneous Connective Tissue Diseases. <i>Medical Clinics of North America</i> , 2021, 105, 757-782.	2.5	3
58	Treatment With Mycophenolate Mofetil for Salt-and-Pepper Dyspigmentation Caused by Autoimmune Sclerosing Disease. <i>JAMA Dermatology</i> , 2022, 158, 327.	4.1	3
59	Approach to and Management of the Neutrophilic Dermatoses. <i>Current Dermatology Reports</i> , 2016, 5, 18-29.	2.1	2
60	Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 850-851.	2.0	2
61	Intravenous Immunoglobulin for Refractory Eosinophilic Fasciitis: A Retrospective Analysis from 3 Tertiary Care Centers. <i>Journal of the American Academy of Dermatology</i> , 2019, , .	1.2	2
62	Willingness-to-pay stated preferences in cutaneous lupus erythematosus: a pilot study. <i>Archives of Dermatological Research</i> , 2020, 312, 527-531.	1.9	2
63	Tense Bullae on the Palms and Soles. <i>JAMA Dermatology</i> , 2015, 151, 99.	4.1	1
64	Dermatology subspecialty clinic for patients with connective tissue disease impacts diagnosis and treatment: A single-center, retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 476-478.	1.2	1
65	Lack of association between tumor necrosis factor- α inhibitor use and exacerbation of lupus erythematosus: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	1
66	The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 517-519.	1.2	1
67	Dermatology education in internal medicine residency programs: A nationwide survey of program directors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 482-484.	1.2	1
68	Race and gender differences in systemic sclerosis: a retrospective multicenter cohort. <i>International Journal of Dermatology</i> , 2022, 61, .	1.0	1
69	Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy. <i>JAMA Dermatology</i> , 2021, , .	4.1	1
70	Crowdsourcing as a means of fundraising for juvenile dermatomyositis. <i>Pediatric Dermatology</i> , 2022, 39, 379-381.	0.9	1
71	Identifying When Therapy for One Skin Disease Is Likely to Exacerbate Another Skin Condition. <i>Archives of Dermatology</i> , 2011, 147, 836.	1.4	0
72	Porphyria Cutanea Tarda Masquerading as Systemic Sclerosis: Two Cases Demonstrating an Important Clinical Observation. <i>Journal of Rheumatology</i> , 2021, 48, 145-146.	2.0	0